Citi raised the firm’s price target on Fresenius Medical (FMS) to EUR 46.50 from EUR 41 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target raised to EUR 55 from EUR 47 at Berenberg
- Fresenius Medical price target raised to $25 from $23 at Truist
- Fresenius Medical Care Rejoins DAX 40, Signifying Strategic Success
- Fresenius Medical Care Announces Release of Bond Guarantee
- Cara Therapeutics, Tvardi Therapeutics enter definitive merger agreement